title: Pimecrolimus, yet another intriguing topical immunomodulator.
abstract: Pimecrolimus, yet another intriguing local immunomodulator, has been approved for use in atopic dermatitis in individuals of more then 2 years of age. However, its indications are now being extended to include a variety of inflammatory dermatoses, which are identified in the current article with a proviso that their use should be considered only as an alternative when conventional modalities have failed.
authors.affiliation: Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Delhi, India. drsehgal@ndf.vsnl.net.in
authors.forename: Virendra N
authors.initials: VN
authors.lastname: Sehgal
authors.forename: Manish
authors.initials: M
authors.lastname: Pahwa
mesh_terms: D000279:Administration, Cutaneous; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; C117268:pimecrolimus; D016559:Tacrolimus